Status: Recruiting
Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies
The purpose of this study is to assess the feasibility, safety, and efficacy of anti-PD-1 antibody alone or in combination with low-dose decitabine in patients with relapsed or refractory malignancies, including Non-Hodgkin'lymphoma, Hodgkin'lymphoma, gastrointestinal cancers, hepatocellular carcinoma, breast cancer, ovarian cancer or lung cancer or renal-cell cancer or pancreatic cancer or bile duct cancer.
Participants needed: 250
Trial details
Phase: Phase 1, Phase 2Age: 12-75Biological sex: AllType: InterventionalSponsor: Han weidongUpdated: Jan 22, 2026Locations: 1
Eligibility criteria
Subjects must have histological confirmation of relapsed or refractory malignanc... [+11]
Subjects with any autoimmune disease or history of syndrome that requires cortic... [+5]